Afatinib: Phase II data

A Korean Phase II trial in 38 evaluable patients with wild-type EGFR stage IIIb/IV NSCLC who failed 2 lines of chemotherapy showed that once-daily 40 mg oral afatinib led to a DCR of 24% with a median...